Danaher ge biopharma investor presentation. GE Chairman and CEO H.

Danaher ge biopharma investor presentation. 4 billion deal announced Monday. 4 billion. 24 Danaher Diagnostics Investor & Analyst Event Event Details Presentation Listen to the Webcast 6:00pm - 1:00pm EDT Feb 25, 2019 · With respect to the non-GAAP financial measures referenced in the following presentation, the accompanying information required by SEC Regulation G can be found in the back of the presentation. 4 billion deal, as the conglomerate looks to slim down its operations and pay off its l Apr 30, 2020 · The combined revenue of the businesses, which were part of Danaher's Life Sciences segment, was approximately $170 million in 2019. Danaher sold these businesses in order to obtain regulatory approval for its acquisition of the GE Biopharma business, now called Cytiva. Gugino - Danaher Corporation - VP of IR Thanks Oct 21, 2019 · Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process WASHINGTON, Oct. m. The acquisition will expand Danaher's life sciences Apr 5, 2020 · My last article on Danaher discuss how the GE Biopharma deal would be a positive for the company. Feb 25, 2019 · Joyce continued, "We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market. Founded in 1984 by brothers Steven and Mitchell Rales, the company has evolved from a real estate investment firm into a high-tech industrial conglomerate. The deal will establish the business as a stand-alone company within Danaher’s existing Life Sciences platform and give it access to additional resources to grow. 4 billion deal, General Electric will narrow its portfolio by selling its biopharma business to Danaher, a Washington, D. 2 billion in annual revenue in 2019, with 75% considered recurring. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s Mar 11, 2025 · Through targeted acquisitions, Danaher has expanded its presence across key industries. Mar 31, 2020 · BOSTON, Mass. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s We present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. On the GE Biopharma deal, Danaher was able to finance the debt at sub 1 percent—an unprecedented funding cost level. Feb 25, 2019 · Danaher will buy the biopharmaceutical business of General Electric in a $21. Feb 25, 2019 · You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations. 24 - 09. Veralto will begin "regular way" trading on the New York Stock Exchange on October 2, 2023, under the symbol "VLTO. com, under the heading “Quarterly Earnings. ” In addition, in addressing various Apr 1, 2020 · Cytiva is the new name of the former GE Healthcare Life Sciences biopharma business following its acquisition by Danaher Corporation, according to an April 1, 2020 announcement. (Operator Instructions) I would now like to turn the conference over to Matt Gugino, Vice President of Investor Relations. We look All references in this presentation (1) to company-specific financial metrics relate only to the continuing operations of Danaher’s business, unless otherwise noted; (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated; (3) to Operating Profit below the segment level exclude amortization; and (4) to “today” refers to the Q1 2025 Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions", “Core” and “FX”, please refer to Danaher’s most recent Quarterly and Annual Reports filed with the SEC, which are available in the “Investors” section of Danaher’s website under the subheading "Financial Reports”. Presentation We invite you to join us for our Investor & Analyst Event in Washington, D. 19 Presentation 8:30am EST Mar 31, 2020 · WASHINGTON, March 31, 2020 / PRNewswire / -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's (NYSE: GE) Life Sciences division. 4 billion addition of GE Healthcare’s Biopharma business will complement Pall’s technologies to bring biomanufacturers a fully end-to-end bioprocessing offering. With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. Given anticipated tax benefits from the transaction structure, the net purchase price is Mar 8, 2019 · The deal to sell General Electric 's (NYSE: GE) biopharma business to Danaher(NYSE: DHR) grabbed the headlines recently. Federal Trade Commission (the “FTC”) in connection with GE’s definitive agreement to sell its BioPharma business to Danaher for approximately $20 billion of net proceeds. The General Electric segment brought in about $3 billion in sales in 2018. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s Lab market expected to grow low- to mid-single digit Pharma and biopharma the largest customer group; rising number and complexity of drugs in development as main demand driver Battery, electronics, food & beverage also fast growing R&D segments in industrial markets Growth driven by R&D spending in the individual end markets Feb 25, 2019 · General Electric has moved to sell its growing biopharma manufacturing business to Danaher in a $21. —March 31, 2020—GE (NYSE:GE) announced today the completion of the sale of its BioPharma business to Danaher Corporation (NYSE:DHR) (“Danaher”) for approximately $20 billion of net proceeds. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large Feb 25, 2019 · GE announced plans on Monday to sell its BioPharma business to Danaher for approximately $21. We see meaningful opportunities to harness the power of the Danaher Business System to further provide GE Biopharma's customers with end-to-end bioprocessing solutions that help enable breakthrough development and production capabilities. com. com, under the heading Events & Presentations and will remain on the website for 1 week. Jan 2, 2025 · Danaher Corporation, a global leader in life sciences, diagnostics, and environmental solutions, has become synonymous with operational excellence and strategic growth. Feb 25, 2019 · Danaher Corporation announced it will acquire the Biopharma business of GE Life Sciences for $21. Feb 28, 2019 · The acquisition will add GE BioPharma’s approximately $2. As part of Danaher, the business Jan 30, 2020 · These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's Feb 25, 2019 · You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations. 05. 25, 2019 / PRNewswire / -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company") announced today that it has entered into a definitive agreement with General Electric Company ("GE") (NYSE: GE) to acquire the Biopharma business of GE Life Sciences ("GE Biopharma") for a cash purchase price of approximately $21. Jul 18, 2019 · These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's This call will be recorded and posted on the Danaher website, www. 4 billion, with shares in the company jumping 16 percent upon the news. Explore now! Mar 19, 2020 · Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21. 4 billion all cash deal, the companies announce. ET. With respect to any non-GAAP financial measures included in the following presentation, the accompanying information required by SEC Regulation G can be found in the “Investors” section of Danaher’s website, www. Feb 25, 2019 · Danaher stock was on its way up Monday following news of a deal to acquire General Electric's (GE) Biopharma business for $21. September 2024 09. Mar 19, 2020 · WASHINGTON, March 19, 2020 / PRNewswire / -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that the U. 25. Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company") announced today that it has entered into a definitive agreement with General Electric Company ("GE") (NYSE: GE) to acquire the Biopharma business of GE Life Sciences ("GE Biopharma") for a cash purchase price of approximately $21. GE currently expects to close the Cytiva’s team of nearly 16,000 associates in more than 40 countries is driven to use their expertise and talent to achieve better flexibility, capacity, and efficiency for customers. The These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's Joyce continued, "We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market. on Wednesday, September 4 and Thursday, September 5, 2024 where we will provide a comprehensive overview of Danaher’s Diagnostics businesses. said the deal was a “pivotal milestone” that “demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and With respect to the non-GAAP financial measures referenced in the following presentation, the accompanying information required by SEC Regulation G can be found in the back of the presentation and in the “Investors” section of Danaher’s web site, www. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s Exec-Director PharmNXT | Ex-CEO | GE | Danaher | 240M $ P&L Management | Founding Promoter & Investor | IISc, IIM, ISB · A distinguished researcher from the prestigious Indian Institute of Science (IISc), coupled with a stellar academic background as an alumnus of both the Indian Institutes of Management (IIM) and the Indian School of Business (ISB), brings forth a remarkable blend of At this time, I would like to welcome everyone to the Danaher Corporation and GE Biopharma Acquisition Conference Call. said the deal was a “pivotal milestone” that “demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's Apr 22, 2025 · Danaher Corporation (NYSE: DHR) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Apr 18, 2019 · These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. Jul 23, 2020 · We also present core sales from continuing operations on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. com, under the heading “Financial Reports” and subheading “Quarterly Earnings. Stay up to date on results, trends, innovations, developments, and more. com, under the heading “Events & Presentations,” and event name “Danaher 2016 Investor & Analyst Meeting. Gugino, you may begin your conference. Feb 25, 2019 · The BioPharma business, which is part of GE Healthcare’s Life Sciences division, generated approximately $3 billion in revenue last year. Apr 22, 2025 · You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations. -based corporation that has become a larger player in life sciences over the past few years through acquisitions. Mar 19, 2020 · BOSTON, Mass. Gugino - Danaher Corporation - VP of IR Thanks With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. 4 billion, this strategic move positions Danaher to enhance its bioprocessing capabilities, offering a comprehensive portfolio of technologies and services. In addition to presenting core sales, we also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. BioProcess Insider reported the news that Danaher Corporation has agreed to buy the Biopharma division of GE Healthcare’s Mar 31, 2020 · WASHINGTON, March 31, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's (NYSE: GE) Life Sciences division. 18 Danaher DBS Overview Transcript Cytiva is a provider of leading life sciences brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. —March 19, 2020—GE (NYSE:GE) announced that, together with Danaher Corporation (NYSE:DHR) (“Danaher”), it has entered into a consent decree agreement with the U. Federal Trade Commission (the "FTC") has accepted the proposed consent order in connection with Danaher's definitive agreement with General Electric Company ("GE") (NYSE: GE) to acquire the Biopharma business of GE Life Sciences ("GE Biopharma"). Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired businesses recorded prior Feb 25, 2019 · In a $21. Stock Information Corporate Governance Contacts & Alerts Danaher Business System Presentation 05. As part of Danaher, the business will be Feb 25, 2019 · Danaher will buy GE's biopharma unit in a $21. All references in this presentation (1) to financial metrics Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. We look Sep 30, 2023 · WASHINGTON, Sept. The decision to create ‘The Biotechnology Group’ by merging Danaher’s two bioprocess businesses was announced at the firm’s 2022 Investor & Analyst event last week. WASHINGTON - Danaher Corporation announced today the completion of its acquisition of the Biopharma business from General Electric Company's Life Sciences division. 21, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards Improve drug candidate success rates by 25% with our automation solutions, analytical innovations, and digital solutions. 4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma, would violate federal antitrust law. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s Apr 1, 2020 · Cytiva rises out of GE Healthcare as Danaher completes $21bn deal It’s “absolutely business as usual” says bioprocess vendor Cytiva despite a new owner and an ongoing coronavirus pandemic. " ABOUT DANAHER Forward Looking Statements Statements in this presentation and the accompanying call that are not strictly historical, including statements regarding the proposed acquisition, the expected timetable for completing the transaction, future financial and operating results, the anticipated percentage of GE Biopharma’s 2019 revenues considered recurring, the anticipated geographic and product Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding the Company’s anticipated financial performance for the third quarter and full year 2019 and opportunities and positioning for 2019 and beyond, the anticipated acquisition of GE Biopharma, the expected timetable for completing the acquisition, the anticipated impact These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's In addition to presenting core sales, we also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. 4 BILLION Washington, D. ” All references in this presentation (1) to company-specific financial metrics In a world that’s ever-changing, our customers work to advance innovations that improve human health. Sep 22, 2022 · Combining Cytiva and Pall will create the “broadest” and “deepest” bioprocess product portfolio in the industry, says Danaher Corporation. Danaher Corporation's acquisition of Cytiva, formerly GE Healthcare Life Sciences, marks a significant milestone in the biopharma industry. Our Life Sciences businesses power tools and technologies that support our customers in a wide range of critical activities, whether it’s creating breakthrough cell and gene therapies, ensuring high-quality fluid filtration in labs, or driving the latest advances in molecular oncology. GE Chairman and CEO H. Mr. Now that the dust has settled on the announcement, it's time to look in May 6, 2020 · Danaher will discuss its results during its quarterly investor conference call on May 7, 2020 starting at 7:30 a. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s Mar 31, 2020 · --Danaher Corporation announced today the completion of its acquisition of the Biopharma business from General Electric Company's Life Sciences division. Simple math supports Joyce’s more aggressive growth strategy. com, under the subheading "Events & Presentations. ” All references in this presentation to earnings With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. Browse the latest news here! Jun 19, 2025 · Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we anticipate will or may occur in the future are Stock Information Corporate Governance Contacts & Alerts Danaher to Acquire GE Biopharma Conference Call 02. Images credit: GE Healthcare Life Sciences. The business provides instruments, consumables and software that support biopharmaceutical drug development and manufacturing workflows. 7 billion bioprocessing business to Danaher’s existing Pall bioprocessing business, which has estimated sales of approximately $1 billion, according to a 2018 Danaher investor presentation. Lawrence Culp Jr. S. By adding companies like Cytiva and Pall Corporation. We see meaningful opportunities to harness the power of the Danaher Business System to further provide GE Biopharma’s customers with end-to-end bioprocessing solutions that help enable breakthrough development and production capabilities. " About Danaher Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Matthew E. ". The acceptance by the FTC With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. 04. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www. Given anticipated tax benefits from the Feb 25, 2019 · General Electric is selling its biopharma business for $21. Feb 25, 2019 · BOSTON - February 25, 2019 - GE (NYSE:GE) announced a definitive agreement to sell its BioPharma business to Danaher Corporation (NYSE: DHR) (“Danaher”) for a total consideration of $21. ” In addition, in addressing various With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in the back of the presentation and in the “Investors” section of Danaher’s web site, www. , February 25, 2019 – Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”) announced today that it has entered into a definitive agreement with General Electric Company (“GE”) (NYSE: GE) to acquire the Biopharma business of GE Life Sciences (“GE Sep 26, 2014 · GE announced plans on Monday to sell its BioPharma business to Danaher for approximately $21. Feb 28, 2019 · The $21. Completed for $21. " "Today marks an exciting milestone for Danaher. 4 billion, including $21 billion in cash as well as Danaher’s assumption of certain pension liabilities. 4 billion, including $21 billion in cash. " ABOUT DANAHER Oct 21, 2019 · These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding the Company’s anticipated future financial performance, the anticipated acquisition of GE Biopharma, the expected timetable for completing the acquisition, the anticipated impact of the acquisition on Danaher and any other statements regarding events or developments With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www. ABOUT DANAHER Danaher is a Feb 25, 2019 · WASHINGTON, Feb. 40 billion. 3-billion global life sciences company with nearly 7000 employees in 40 countries. Exhibit 99. Beginning with respect to forecasted results for the second quarter of 2020, we also present core revenue from continuing operations on a basis that includes revenue attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. The new company and name, which is now part of the Danaher Corporation Life Sciences platform, will be a $3. " ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. C. Jan 28, 2021 · We also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company's ("GE") Life Sciences business), which Danaher acquired from GE on March 31, 2020. 1 DANAHER TO ACQUIRE THE BIOPHARMA BUSINESS OF GENERAL ELECTRIC LIFE SCIENCES FOR $21. The acquisition underscores Danaher's commitment to advancing biological Sep 6, 2019 · Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy GE Healthcare’s Biopharma business has announced plans to change its name and logo in anticipation of its acquisition by Danaher later this year Read Danaher Corporation news. 24. 30, 2023 / PRNewswire / -- Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation. These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's Jan 27, 2022 · We also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company's ("GE") Life Sciences business), which Danaher acquired from GE on March 31, 2020. ” In addition, in addressing various At this time, I would like to welcome everyone to the Danaher Corporation and GE Biopharma Acquisition Conference Call. com, under the heading “Events and Presentations”. It is expected to generate $3. danaher. qvvdh vfrl trprz vln mkojeht aqxno tahhjfo qdsbif fymsm asalhv